Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907003 | 0.86 | DRD2 (0.62) | DRD2DRD3DRD1DRD5ACHE | |
| SCHEMBL268506 | 0.85 | DRD2 (0.49) | DRD2DRD3DRD1DRD5ACHE | |
| SCHEMBL29396439 | 0.85 | DRD2 (0.49) | DRD2DRD3DRD1DRD5ACHE | |
| SCHEMBL266381 | 0.85 | DRD2 (0.55) | DRD2DRD3DRD1DRD5ACHE | |
| SCHEMBL2061100 | 0.84 | DRD2 (0.47) | DRD2DRD3DRD1DRD5ACHE | |
| SCHEMBL2061606 | 0.84 | DRD2 (0.54) | DRD2DRD3DRD1DRD5ACHE | |
| SCHEMBL6901761 | 0.84 | DRD2 (0.56) | DRD2DRD3DRD1DRD5HTR2A | |
| Ammonia Solution, Strong SCHEMBL3583671 | 0.84 | DRD2 (0.61) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL28263467 | 0.80 | DRD2 (0.67) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL6583999 | 0.79 | KDM4E (0.52) | CYP1A2ACHEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLIXOGEN THERAPEUTICS LTD. (IL) | 2023-08-03 | — | — | US | disclosed |
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLIXOGEN THERAPEUTICS LTD. (IL) | 2023-08-03 | — | — | US | disclosed |
| WO-2023088406-A1 | FUSED IMIDE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2021229583-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLIXOGEN THERAPEUTICS LTD. (IL) | 2021-11-18 | — | — | WO | disclosed |
| US-20170368028-A1 | N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-28 | — | — | US | disclosed |
| EP-2569277-B1 | SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF | BAYER IP GMBH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8673903-B2 | Substituted 8-alkoxy-2-aminotetralin derivatives, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20130203751-A1 | SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| EP-2569277-A1 | SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141409-A1 | SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203751-A1 | SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF | AADAT, TNNT2, TNNI3 | DRD2 1081/4885DRD3 1624/4885DRD1 2199/4885 |
| US-20170368028-A1 | N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF | RORC, RORB, RORA | DRD2 4682/4885DRD3 3803/4885DRD1 4123/4885 |
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLI1, SHH, GLI2 | DRD2 3824/4885DRD3 3884/4885DRD1 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.